Conaghan, Philip G. http://orcid.org/0000-0002-3478-5665
Arden, Nigel
Avouac, Bernard
Migliore, Alberto
Rizzoli, René
Article History
First Online: 9 May 2019
Compliance with Ethical Standards
: The authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval of the version to be published.
: The ESCEO Working Group was entirely funded by the ESCEO, a Belgian not-for-profit organization that receives unrestricted educational grants, to support its educational and scientific activities, from non-governmental organizations, not-for-profit organizations, and non-commercial and corporate partners. The choice of topics, participants, content and agenda of the working groups, as well as the writing, editing, submission and reviewing of the manuscript, are under the sole responsibility of the ESCEO, without any influence from third parties.
: Philip G. Conaghan reports consultancy fees or speakers’ bureau fees from Abbvie, BMS, Flexion Therapeutics, GlaxoSmithKline, Merck Serono, Novartis, Pfizer, Roche and Samumed outside of the submitted work. Nigel Arden reports personal fees from Bioventus, Flexion, Merck, Pfizer/Lilly, Regeneron, Smith & Nephew and Freshfields Bruckhaus Deringer, as well as grants from Bioiberica and Merck, outside of the submitted work. Alberto Migliore reports fees for participation in review activities from Fidia, MSD, Sanofi and Novartis, and payment for lectures from Roche, GUNA, Ibsa, Abiogen and Pfizer, outside of the submitted work.